Abstract: An assembly for retaining a pressure jacket (134) and a syringe (132) on a fluid injector, the assembly including a base plate (1902) comprising a body (1904); at least a first retaining arm (1910a) and a second retaining arm (1910b) operatively mounted on the body of the base plate, the first retaining arm having a first retaining surface at a distal end thereof and the second retaining arm having a second retaining surface at a distal end thereof, wherein the first retaining surface and the second retaining surface are configured for abutting a distal surface of at least one of the pressure jacket and the syringe; a linkage assembly operatively connected to at least one of the first retaining arm and the second retaining arm, wherein the linkage assembly is configured to move at least one of the first retaining arm and the second retaining arm between at least a first open position and a closed position.

Abstract: Described is a method of providing an estimate of radiation dose received by a patient during an imaging scan performed by an imaging system. The method includes receiving patient information about the patient, receiving scan data generated during the imaging scan of the patient by the imaging system, creating a virtual dose model of the patient based upon the patient information and the scan data, receiving a selection of a region of interest of the patient, performing a dose simulation on the virtual dose model of the patient or a portion thereof, and determining, based upon an outcome of the dose simulation, an estimate of the radiation dose received within the region of interest. The imaging scan can be a partial imaging scan of a portion of the patient. Also provided is a system and software for carrying out this method.

Abstract: A method is provided for authenticating, and establishing and tracking eligibility of a patient to purchase an over-the-counter (OTC) drug from a retailer, the patient using a client device or terminal and the retailer having a server. The server is configured to redirect the client device or terminal to a backend platform to authenticate the patient, access a storage to search for any information that indicates the patient is ineligible to purchase the OTC drug; and without any information that indicates the patient is ineligible, administer a questionnaire to the patient to assess the eligibility for the OTC drug. And the backend platform redirects the client device or terminal back to the server to complete the online sale of the OTC drug to the patient when the patient is eligible, or cancel the online sale of the OTC drug to the patient when the patient is ineligible.

Abstract: The present disclosure is concerned with the technical field of marking objects with optically readable codes and reading out (decoding) the codes. Subjects of the present disclosure are a method, a system and a computer program product for decoding optically readable codes introduced in surfaces of objects.

Abstract: Systems, methods, and computer programs disclosed herein relate to training a machine learning model to generate multimodal representations of objects, and to the use of said representations for predictive purposes.

Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

Abstract: A system, method, and computer program product for predicting, anticipating, and/or assessing tissue characteristics obtains measurement information associated with a parameter of a voxel of tissue of a patient measured at two or more time points, the two or more time points occurring before one or more characteristics of the voxel of the tissue are separable in an image generated based on the parameter of the voxel measured at a single time point of the two or more time points, and determines, based on the parameter of the voxel at the two or more time points, the one or more characteristics of the voxel of the tissue.

Abstract: The invention relates to an inserter for an intrauterine system, including a handle (3) having a longitudinal opening (8) at its first end, the opening (8) having a longitudinal axis parallel to the longitudinal axis of the inserter, a first end (8a) and a second end (8b), a moveable slider (5) arranged in the longitudinal opening (8) and having a first end (5a) and a second end (5b), a plunger (2) attached to the handle (3), an insertion tube (6) arranged around the plunger (2) having a first end and a second end, with its second end attached to the slider (5). The inserter further includes a lock that reversibly locks the intrauterine system in relation to the plunger (2) via a removal string of the intrauterine system, the lock being controllable by the slider (5) and/or the insertion tube (6).

Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

Abstract: The invention relates to a method for transferring a pourable medium (10) from a first vessel (12) into a second vessel (14), by means of a robot arm (16), wherein a movement 118) of the robot arm (16) can be controlled by at least one movement parameter (BP), including, inter alia, the following method steps: d) determining the mass of the medium (10) transferred into the second vessel (14) as an actual filling mass (IFM), and also the variation over time of the actual filling mass (IFM) of the medium (30; as an actual mass flow (IMS), by means of a balance 124), c) calculating a correcting mass flow (StMS) as a correcting variable (26) of a first control circuit (28) while taking into account the actual filling mass (FM) and the intended filling mass (SFM), f) using the correcting variable (26) of die first control circuit (28) as a reference variable (30) of a second control circuit (32) for the purpose that the calculated correcting mass flow (StMS) is used as the intended mass flow (SMS), g) calculating

Abstract: This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.

Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.

Abstract: A method for providing a prediction of a representation of an examination region that was generated using a medical image technique involving a contrast agent may include receiving a first representation in frequency space of an examination region of an examination object, receiving a second representation in the frequency space of the examination region of the examination object, providing the first representation and the second representation as an input to a predictive machine learning model that is configured to provide, as an output, a prediction of a representation in the frequency space of the examination region with an amount of the contrast agent administered during a medical imaging technique, receiving the output of the predictive machine learning model based on the input, and converting the output of the predictive machine learning model to a representation in real space of the examination region of the examination object.

Abstract: The present invention relates to the technical field of producing artificial contrast-enhanced radiological images by way of machine learning methods.

Abstract: A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.

Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):

Abstract: Benzoylamides of the general formula (I) are described as herbicides. In this formula (I), B, X1 and X2 represent N, O or S(O)n. R, Ra, Rb and Rx represent radicals such as hydrogen, halogen, (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C1-C6)-alkyloxy and cyano.

Abstract: This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.

Abstract: The present invention related to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I)

Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also the preparation and use of the crystalline polymorph I of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I).